BACKGROUND: Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU). OBJECTIVES: To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients, as well as to compare the public expenditures on OMPs in 8 EU member states. METHODS: Information on the reimbursement status of 83 OMPs was collected in 8 countries by distinguishing standard and special reimbursements. In two consecutive years, the total public expenditures on OMPs were calculated by using annual EUR exchange rates. Annual total public expenditures were calculated per capita, and as a proportion of GDP, total public pharmaceutical and healthcare budgets. Differences between countries were compared by calculating the deviations from the average spending of countries. RESULTS: In 2015 29.4-92.8% of the 83 OMPs were available with any kind of public reimbursement in participant countries including special reimbursement on an individual basis. In Austria, Belgium and France more OMPs were accessible for patients with public reimbursement than in Bulgaria, Czech Republic, Hungary and Poland. Standard reimbursement through retail pharmacies and/or hospitals was applied from 0 to 41% of OMPs. The average annual total public expenditure ranged between 1.4-23.5 €/capita in 2013 and 2014. Higher income countries spent more OMPs in absolute terms. Participant countries spent 0.018-0.066% of their GDPs on funding OMPs. Average expenditures on OMPs were ranged between 2.25-6.51% of the public pharmaceutical budget, and 0.44-0.96% of public healthcare expenditures. CONCLUSIONS: Standard and special reimbursement techniques play different roles in participant countries. The number of accessible OMPs indicated an equity gap between Eastern and Western Europe. The spending on OMPs as a proportion of GDP, public pharmaceutical and healthcare expenditure was not higher in lower income countries, which indicates substantial differences in patient access to OMPs in favour of higher-income countries. Equity in access for patients with rare diseases is an important policy objective in each member state of the EU; however, equity in access should be harmonized at the European level.

Department of Health Economics Ludwig Boltzmann Institute Garnisongasse 7 20 A 1090 Vienna Austria

Department of Health Policy and Health Economics Institute of Economics Faculty of Social Sciences Eötvös Loránd University Pázmány Péter sétány 1 A 1117 Budapest 361 Hungary

Department of Organization and Economics of Pharmacy Medical University Sofia Bulgaria Dunav str 2 1000 Sofia Bulgaria

French National Authority for Health 5 avenue du Stade de France 93218 Saint Denis La Plaine Cedex France

Health Insurance Institute of Slovenia Miklošičeva cesta 24 1507 Ljubljana Slovenia

Institute of Genomic Medicine and Rare Disorders Semmelweis University H 1083 Tömő u Budapest 25 29 Hungary

Institute of Public Health Faculty of Health Sciences Jagellonian University Medical College 008 Grzegorzecka 20 31 531 Kraków Poland

Mechanism of Coordinated Access to Orphan Medicinal Products 1150 Vienna Austria

National Institute for Health and Disability Insurance of Belgium Av de Tervuerenlaan 211 1150 Brussels Belgium

State Institute for Drug Control Šrobárova 48 100 41 10 Praha Czech Republic

Syreon Research Institute Mexikói út 65A Budapest 1142 Hungary

Zobrazit více v PubMed

Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet J Rare Dis. 2011;6:62. doi: 10.1186/1750-1172-6-62.1. PubMed DOI PMC

Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis. 2013;8:109. doi: 10.1186/1750-1172-8-109. PubMed DOI PMC

McCabe C. Balancing economic, ethical and equity concerns in orphan drugs and rare diseases. EJHP Pract. 2010;16(4):22–25.

Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–29. doi: 10.1586/erp.11.95. PubMed DOI

Denis A, Mergaert L, Fostier C, Cleemput I, Hulstaert F, Simoens S. Critical assessment of belgian reimbursement dossiers of orphan drugs. PharmacoEconomics. 2011;29(10):883–893. doi: 10.2165/11585980-000000000-00000. PubMed DOI

Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. PubMed DOI PMC

Annemans L, Aymé S, Le Cam Y, Facey K, Gunther P, Nicod E, Reni M, Roux JL, Schlander M, Taylor D, Tomino C, Torrent-Farnell J, Upadhyaya S, Hutchings A, Le Dez L. Recommendations from the European working Group for Value Assessment and Funding Processes in rare diseases (ORPH-VAL) Orphanet J Rare Dis. 2017;12(1):50. doi: 10.1186/s13023-017-0601-9. PubMed DOI PMC

European Commission. Live, work, travel in the EU. Public Health. Non-communicable diseases. Steering Group. https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en. Accessed 12 Oct 2018.

European Commission. Directorate General. Health and Food Safety. Public health. Medicinal products for human use. Orphan medicinal products. http://ec.europa.eu/health/human-use/orphan-medicines/index_en.htm. Accessed 15 Apr 2016.

Official Journal of the European Communities. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. 22.1.2000. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed 15 Apr 2016.

European Medicines Agency. Human. European Public Assessment Reports.Orphan designations. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/ema_group_types/ema_orphan. Accessed 12 Oct 2018.

Orphanet. Inventory of orphan drugs. http://www.orpha.net/consor/cgi-bin/Drugs.php?lng=EN. Accessed 15 Apr 2016.

Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42. doi: 10.1017/S0266462307051550. PubMed DOI

Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74. doi: 10.1186/1750-1172-7-74. PubMed DOI PMC

Nestler-Parr Sandra, Korchagina Daria, Toumi Mondher, Pashos Chris L., Blanchette Christopher, Molsen Elizabeth, Morel Thomas, Simoens Steven, Kaló Zoltán, Gatermann Ruediger, Redekop William. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health. 2018;21(5):493–500. doi: 10.1016/j.jval.2018.03.004. PubMed DOI

Simoens S. Pricing and reimbursement of orphan drugs: the need for more transpar-ency. Orphanet J Rare Dis. 2011;6(1):42. doi: 10.1186/1750-1172-6-42. PubMed DOI PMC

Côté A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15(8):1185–1191. doi: 10.1016/j.jval.2012.09.004. PubMed DOI

Zelei T, Molnar M, Szegedi M, Kaló Z. Systematic review on the evaluation criteria of orphan medicines in central and eastern European countries. Orphanet J Rare Dis. 2016;11(1):72. doi: 10.1186/s13023-016-0455-6. PubMed DOI PMC

Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy. 2010;8(5):343–350. doi: 10.2165/11536990-000000000-00000. PubMed DOI

Rodwell C, Aymé S. Rare disease policies to improve care for patients in Europe. Biochim Biophys Acta. 2015;1852:2329–2335. doi: 10.1016/j.bbadis.2015.02.008. PubMed DOI

Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, Simoens S. Rec-onciling uncertainty of costs and outcomes with the need for access to orphan medici-nal products: a comparative study of managed entry agreements across seven Europe-an countries. Orphanet J Rare Dis. 2013;8(1):1983. doi: 10.1186/1750-1172-8-198. PubMed DOI PMC

Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–741. doi: 10.1586/14737167.2013.847367. PubMed DOI

Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S. Market uptake of orphan drugs - a European analysis. J Clin Pharm Ther. 2012;37(6):664–667. doi: 10.1111/j.1365-2710.2012.01364.x. PubMed DOI

Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy. 2012;108(1):10–18. doi: 10.1016/j.healthpol.2012.08.013. PubMed DOI

Orphanet: List of orphan drugs with MA. http://www.orpha.net/consor/cgi-bin/Drugs_ListOrphanDrugs_List.php?lng=EN&TAG=A. Accessed 27 July 2015

European Medicines Agency. Human. European Public Assessment Reports. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine. Accessed 12 Oct 2018.

O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia. 2013;19(4):e239–e247. doi: 10.1111/hae.12125. PubMed DOI

European Network for Health Technology Assessment (EUnetHTA). https://www.eunethta.eu/. Accessed 3 Sept 2018.

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL On health technology assessment and amending Directive 2011/24/EU; COM(2018) 51 final; 2018/0018 (COD); EUROPEAN COMMISSION; Brussels, 31.1.2018. https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/com2018_51_en.pdf.

Garau M, Hampson G, Devlin N, Mazzanti NA, Profico A. Applying a multicriteria decision analysis (MCDA) approach to elicit Stakeholders’ preferences in Italy: the case of Obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL) Pharmacoecon Open. 2018;2(2):153–163. doi: 10.1007/s41669-017-0048-x. PubMed DOI PMC

Mechanism of Coordinated Access to orphan medicinal products (MoCA). https://www.eurordis.org/content/moca. Accessed 3 Sept 2018.

The BeNeLuxA Initiative on Pharmaceutical Policy. HTA Activities. http://www.beneluxa.org/hta. Accessed 11 Sept 2018.

Optimizing Patient Access to Orphan Medicinal Products: Lessons from Central and Eastern Europe

Novel approach to decision making for orphan drugs

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries